Collegium Pharmaceutical Inc Forecasted to Earn FY2020 Earnings of $1.11 Per Share (COLL)

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Research analysts at Jefferies Group lifted their FY2020 earnings per share (EPS) estimates for Collegium Pharmaceutical in a research report issued on Sunday. Jefferies Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will earn $1.11 per share for the year, up from their previous forecast of $0.93. Jefferies Group currently has a “Buy” rating and a $32.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. Piper Jaffray Companies set a $33.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Monday. Janney Montgomery Scott set a $26.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, November 17th. Finally, Needham & Company LLC increased their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Collegium Pharmaceutical currently has an average rating of “Buy” and a consensus price target of $27.17.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded up $0.75 during mid-day trading on Tuesday, reaching $24.37. The company’s stock had a trading volume of 392,400 shares, compared to its average volume of 661,402. The stock has a market capitalization of $806.54 and a P/E ratio of -8.34. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $26.77.

In other news, Chairman Michael Thomas Heffernan sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total value of $500,200.00. Following the transaction, the chairman now owns 535,395 shares in the company, valued at $13,390,228.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Alison B. Fleming sold 4,029 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the completion of the transaction, the chief technology officer now owns 28,513 shares in the company, valued at approximately $484,721. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,055,558 shares of company stock worth $18,570,177. Company insiders own 25.76% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Bank of New York Mellon Corp lifted its position in shares of Collegium Pharmaceutical by 60.7% in the second quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock valued at $1,313,000 after acquiring an additional 39,656 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Collegium Pharmaceutical by 76.9% in the second quarter. Alliancebernstein L.P. now owns 27,600 shares of the specialty pharmaceutical company’s stock valued at $345,000 after purchasing an additional 12,000 shares during the last quarter. Teachers Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 98.8% in the second quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock valued at $745,000 after purchasing an additional 29,617 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in shares of Collegium Pharmaceutical by 44.0% in the second quarter. TIAA CREF Investment Management LLC now owns 61,187 shares of the specialty pharmaceutical company’s stock valued at $765,000 after purchasing an additional 18,691 shares during the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after purchasing an additional 2,802 shares during the last quarter. Institutional investors and hedge funds own 82.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Collegium Pharmaceutical Inc Forecasted to Earn FY2020 Earnings of $1.11 Per Share (COLL)” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/02/14/collegium-pharmaceutical-inc-forecasted-to-earn-fy2020-earnings-of-1-11-per-share-coll.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply